Company intelligence / Profile preview

Domain Partners

Strasbourg, Grand Est, France

Ownership: Private
Employees: ~108
Development stage: Other

Overview

Clinical-stage biopharma with Phase 1 programs in immuno-oncology (DT-9081 EP4R antagonist and DT-7012 anti-CCR8 antibody) and preclinical PAR2 antagonist for inflammation.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Partnerships

Ono PharmaceuticalMerck KGaAPfizerBristol Myers SquibbBoehringer IngelheimUniversité de Montréal

Beyond the preview

Go deeper on Domain Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Domain Partners.

Explore the full profile